IGC Pharma annual gross margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
IGC Pharma Gross Margin Growth & History (IGC)
IGC Pharma's gross margin was 48.70% for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-03-31 | 48.70% | −5.80 pp |
| 2024 | 2024-03-31 | 54.50% | +5.98 pp |
| 2023 | 2023-03-31 | 48.52% | −18.61 pp |
| 2022 | 2022-03-31 | 67.13% | +54.54 pp |
| 2021 | 2021-03-31 | 12.58% | +9.76 pp |
| 2020 | 2020-03-31 | 2.82% | +0.24 pp |
| 2019 | 2019-03-31 | 2.58% | −1.16 pp |
| 2018 | 2018-03-31 | 3.74% | −33.86 pp |
| 2017 | 2017-03-31 | 37.60% | — |
IGC Pharma quarterly gross margin
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | 18.11% | −28.55 pp |
| Q1 2026 · Mar 31 | 2026-03-31 | 17.35% | −23.12 pp |
| Q2 2026 · Sep 30 | 2025-09-30 | 51.83% | +3.77 pp |
| Q1 2026 · Jun 30 | 2025-06-30 | 46.95% | −12.98 pp |
| Q4 2025 | 2025-03-31 | 46.67% | −11.30 pp |
| Q3 2025 | 2024-12-31 | 40.47% | −24.73 pp |
| Q2 2025 | 2024-09-30 | 48.06% | −11.74 pp |
| Q1 2025 | 2024-06-30 | 59.93% | +13.98 pp |
| Q4 2024 | 2024-03-31 | 57.97% | +19.78 pp |
| Q3 2024 | 2023-12-31 | 65.20% | +34.47 pp |
| Q2 2024 | 2023-09-30 | 59.79% | −7.04 pp |
| Q1 2024 | 2023-06-30 | 45.95% | −21.04 pp |
| Q4 2023 | 2023-03-31 | 38.18% | −447.53 pp |
| Q3 2023 | 2022-12-31 | 30.72% | −12.94 pp |
| Q2 2023 | 2022-09-30 | 66.83% | −1.03 pp |
| Q1 2023 | 2022-06-30 | 66.98% | +33.21 pp |
| Q4 2022 | 2022-03-31 | 485.71% | +452.38 pp |
| Q3 2022 | 2021-12-31 | 43.66% | +30.70 pp |
| Q2 2022 | 2021-09-30 | 67.86% | +47.06 pp |
| Q1 2022 | 2021-06-30 | 33.77% | +25.89 pp |
| Q4 2021 | 2021-03-31 | 33.33% | −21.84 pp |
| Q3 2021 | 2020-12-31 | 12.96% | +7.73 pp |
| Q2 2021 | 2020-09-30 | 20.80% | +19.26 pp |
| Q1 2021 | 2020-06-30 | 7.88% | +5.39 pp |
| Q4 2020 | 2020-03-31 | 55.17% | +53.42 pp |
| Q3 2020 | 2019-12-31 | 5.24% | +1.73 pp |
| Q2 2020 | 2019-09-30 | 1.54% | −0.68 pp |
| Q1 2020 | 2019-06-30 | 2.49% | −0.36 pp |
| Q4 2019 | 2019-03-31 | 1.75% | −3.37 pp |
| Q3 2019 | 2018-12-31 | 3.50% | — |
| Q2 2019 | 2018-09-30 | 2.22% | — |
| Q1 2019 | 2018-06-30 | 2.84% | — |
| Q3 2018 | 2017-12-31 | 5.12% | — |
IGC Pharma gross margin trends
Over the last five reported fiscal years, IGC Pharma's gross margin increased from 2.82% to 48.70%, a change of +45.88 percentage points. The latest reported quarter, Q2 2026 · Jun 30, shows 18.11%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma filings at SEC.gov ↗